Cooperative Agreement U01HL184167
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $441,375 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 15, 2025, with completion targeted for July 31, 2027. The award funds research to develop and optimize a dual adeno-associated virus (AAV) gene delivery system employing intein technology to deliver full-length, functional cystic fibrosis transmembrane...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $361,125 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded April 15, 2026, with completion targeted for March 31, 2028. The grant supports the development of FLUME (Fetal Lung Multiomics Exploration), a human fetal lung multiomics cell atlas with computational models designed to predict fetal origins and molecular...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $727,575 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025, with completion targeted for May 31, 2030. The project will investigate the cellular mechanisms and clinical impact of the genetic variant rs7512462 within the SLC26A9 gene on individual patient responses to cystic fibrosis (CF)...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $511,987 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 27, 2025, with a completion date of May 31, 2029. This award funds a comparative research study investigating the molecular mechanisms of lamin A/C (LMNA)-related dilated cardiomyopathy, a severe form of adult-onset heart disease. The...
- Federal Grant Award Summary Boston Children's Hospital received a $267,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, with completion anticipated by July 31, 2027. The award funds research to identify shared molecular mechanisms underlying congenital heart disease (CHD) and neurodevelopmental delay and disability (NDD) by characterizing dysregulated gene expression in...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $212,407 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 16, 2025, with completion targeted by December 21, 2027. The award funds research focused on the functional characterization of NRAC (Nutritionally Regulated Adipose and Cardiac-Enriched Gene), a novel microprotein involved in lipid...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $249,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of April 2, 2026 and completion date of March 31, 2029. This grant supports research investigating the role of subpleural fibroblasts in pulmonary fibrosis progression, specifically examining how elevated mechanical tension in the...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $249,000 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 25, 2025, with completion targeted for July 31, 2028. The grant supports basic research investigating the molecular mechanisms linking the transcription factor PITX2 (Paired-like Homeodomain Transcription Factor 2) to atrial fibrillation (AF)...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $118,632 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 11, 2025 through July 31, 2027. The funded research project, titled "The Role of Matrifibrocytes in a Fibrotic-like Response During Myxomatous Heart Valve Disease Progression," investigates the mechanisms underlying progressive...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $731,130 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 19, 2025, with a completion date of June 30, 2030. The grant supports a multi-site, two-stage sequential multiple assignment randomized trial (SMART) designed to evaluate the effectiveness of a stepped-care mobile health (mHealth)...
Cincinnati Children's Hospital Medical Center received a $6.45M Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective May 15, 2026 through April 30, 2032. Under this award, Cincinnati Children's will establish and maintain the Bench to Bassinet (B2B) Congenital Heart Disease (CHD) Advancing New Understanding in Genomics (CHANGE) Cohort as a data coordinating center. The organization will conduct deep phenotyping and clinical re-assessment of participants previously enrolled in the CHD Genes study, which has enrolled over 14,000 individuals with CHD and 18,000 family members to date. The primary deliverables include organizing and maintaining the longitudinal B2B CHANGE Cohort, integrating new clinical and phenotypic data sources with existing genomic information housed in the B2B DataHub (HeartSMART), and sharing this integrated dataset with the NHLBI's BioData Catalyst system. Cincinnati Children's will serve as the central coordinating hub, leveraging its cardiovascular research expertise and advanced infrastructure to provide the CHD research community with necessary access, analytical tools, and support services to translate B2B data into improved health outcomes for individuals with congenital heart disease. This initiative aims to address critical gaps in understanding genotype-phenotype correlations and long-term outcomes in CHD while making findings publicly available to the scientific community.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $6.5m | 5/13/26 |